Anticalins: Exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins

FEBS Letters

Volumn 588, Issue 2, 2014, Pages 213-218

  Richter, A ^a   Eggenstein, E ^a   Skerra, A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Combinatorial design; Immunoglobulin; Lipocalin; Protein engineering; Scaffold

Indexed keywords

ANGIOCAL; ANTICALIN; BILIN BINDING PROTEIN; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIGITALIS; DIGOXIGENIN; DUOCALIN; FIBRONECTIN; HAPTEN; HEAT SHOCK PROTEIN 70; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; LANTHANIDE; LIGAND; LIPOCALIN 1; METAL CHELATE; MONOCLONAL ANTIBODY; NANOBODY; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PENTETIC ACID; POLYPEPTIDE; PROTEIN VARIANT; PRS 050; RETINOL; SCAFFOLD PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 3;

ALPHA HELIX; AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; ANTIGEN BINDING; ANTIGEN FUNCTION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; BETA SHEET; BINDING AFFINITY; CELL SURFACE; COMBINATORIAL LIBRARY; COMPLEMENTARITY DETERMINING REGION; CROSS LINKING; CRYSTAL STRUCTURE; DIGITALIS INTOXICATION; DISULFIDE BOND; DNA SYNTHESIS; DRUG OVERDOSE; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; ENDOSOME; FLUORESCENCE; GENE CASSETTE; GENE FUSION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; LIGAND BINDING; MOLECULAR IMAGING; MOLECULAR RECOGNITION; MOLECULAR SIZE; NEOPLASM; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEIN TRANSPORT; RADIOIMMUNOTHERAPY; RECOMBINANT DNA TECHNOLOGY; REVIEW; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TUMOR VASCULARIZATION;

COMBINATORIAL DESIGN; IMMUNOGLOBULIN; LIPOCALIN; PROTEIN ENGINEERING; SCAFFOLD;

ANIMALS; BIOMEDICAL RESEARCH; COMPLEMENTARITY DETERMINING REGIONS; HUMANS; LIPOCALINS; PROTEIN ENGINEERING;

EID: 84892373382     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.11.006     Document Type: Review

References (41)

1. v fragment in Escherichia coli Science 240 1988 1038 1041
2. A. Plückthun, and A. Skerra Expression of functional antibody Fv and Fab fragments in Escherichia coli Methods Enzymol. 178 1989 497 515
3. J.G. Elvin, R.G. Couston, and C.F. van der Walle Therapeutic antibodies: market considerations, disease targets and bioprocessing Int. J. Pharm. 440 2013 83 98
4. J.M. Reichert, and E. Dhimolea The future of antibodies as cancer drugs Drug Discov. Today 17 2012 954 963
5. E.A. Padlan Anatomy of the antibody molecule Mol. Immunol. 31 1994 169 217
6. P. Holliger, and P.J. Hudson Engineered antibody fragments and the rise of single domains Nat. Biotechnol. 23 2005 1126 1136
7. S. Muyldermans et al. Camelid immunoglobulins and nanobody technology Vet. Immunol. Immunopathol. 128 2009 178 183
8. J. Wesolowski et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity Med. Microbiol. Immunol. 198 2009 157 174
9. B. Åkerström, N. Borregaard, D.A. Flower, and J.-S. Salier Lipocalins 2006 Landes Bioscience Georgetown, Texas
10. D.A. Breustedt, D.L. Schönfeld, and A. Skerra Comparative ligand-binding analysis of ten human lipocalins Biochim. Biophys. Acta 1764 2006 161 173
11. D.R. Flower The lipocalin protein family: structure and function Biochem. J. 318 1996 1 14
12. A. Skerra Lipocalins as a scaffold Biochim. Biophys. Acta 1482 2000 337 350
13. G. Winter, and C. Milstein Man-made antibodies Nature 349 1991 293 299
14. G. Beste, F.S. Schmidt, T. Stibora, and A. Skerra Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold Proc. Natl. Acad. Sci. USA 96 1999 1898 1903
15. M. Gebauer, and A. Skerra Anticalins: small engineered binding proteins based on the lipocalin scaffold Methods Enzymol. 503 2012 157 188
16. F.S. Schmidt, and A. Skerra The bilin-binding protein of Pieris brassicae. cDNA sequence and regulation of expression reveal distinct features of this insect pigment protein Eur. J. Biochem. 219 1994 855 863
17. M. Vogt, and A. Skerra Construction of an artificial receptor protein ("anticalin") based on the human apolipoprotein D ChemBioChem 5 2004 191 199
18. D.A. Breustedt, L. Chatwell, and A. Skerra A new crystal form of human tear lipocalin reveals high flexibility in the loop region and induced fit in the ligand cavity Acta Crystallogr. D Biol. Crystallogr. 65 2009 1118 1125
19. D.H. Goetz, M.A. Holmes, N. Borregaard, M.E. Bluhm, K.N. Raymond, and R.K. Strong The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition Mol. Cell 10 2002 1033 1043
20. S. Schlehuber, G. Beste, and A. Skerra A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin J. Mol. Biol. 297 2000 1105 1120
21. J.V. Mercader, and A. Skerra Generation of anticalins with specificity for a nonsymmetric phthalic acid ester Anal. Biochem. 308 2002 269 277
22. S. Vopel, H. Mühlbach, and A. Skerra Rational engineering of a fluorescein-binding anticalin for improved ligand affinity Biol. Chem. 386 2005 1097 1104
23. I.P. Korndörfer, G. Beste, and A. Skerra Crystallographic analysis of an "anticalin" with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region Proteins Struct. Funct. Genet. 53 2003 121 129
24. I.P. Korndörfer, S. Schlehuber, and A. Skerra Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin J. Mol. Biol. 330 2003 385 396
25. A. Skerra Imitating the humoral immune response Curr. Opin. Chem. Biol. 7 2003 683 693
26. M. Gebauer, A. Schiefner, G. Matschiner, and A. Skerra Combinatorial design of an Anticalin directed against the extra-domain B for the specific targeting of oncofetal fibronectin J. Mol. Biol. 425 2013 780 802
27. U. Binder, G. Matschiner, I. Theobald, and A. Skerra High-throughput sorting of an Anticalin library via EspP-mediated functional display on the Escherichia coli cell surface J. Mol. Biol. 400 2010 783 802
28. H.J. Kim, A. Eichinger, and A. Skerra High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2 J. Am. Chem. Soc. 131 2009 3565 3576
29. E. Eggenstein, A. Eichinger, H.J. Kim, and A. Skerra Structure-guided engineering of Anticalins with improved binding behavior and biochemical characteristics for application in radio-immuno imaging and/or therapy J. Struct. Biol. 2013, in press, http://dx.doi.org/10.1016/j.jsb.2013.03.009
30. S. Mocellin, and D. Nitti CTLA-4 blockade and the renaissance of cancer immunotherapy Biochim. Biophys. Acta 1836 2013 187 196
31. D. Schönfeld et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies Proc. Natl. Acad. Sci. USA 106 2009 8198 8203
32. M. Kaspar, L. Zardi, and D. Neri Fibronectin as target for tumor therapy Int. J. Cancer 118 2006 1331 1339
33. C.T. Mendler, and A. Skerra Anticalins: an emerging class of novel biologics to treat cancer and other severe diseases Drug Future 38 2013 169 179
34. V.P. Chekhonin, S.A. Shein, A.A. Korchagina, and O.I. Gurina VEGF in tumor progression and targeted therapy Curr. Cancer Drug Targets 13 2013 423 443
35. K. Mross et al. First in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: results of a dose escalation study Mol. Cancer Ther. 10 2011 A212
36. S.A. Olwill et al. A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity Mol. Cancer Ther. 12 2013 2459 2471
37. M. Steiner, K. Gutbrodt, N. Krall, and D. Neri Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications Bioconjug. Chem. 24 2013 234 241
38. F. Eyer et al. Intravenous application of an anticalin dramatically lowers plasma digoxin levels and reduces its toxic effects in rats Toxicol. Appl. Pharmacol. 263 2012 352 359
39. J. Liu et al. Construction of ribosome display library based on lipocalin scaffold and screening anticalins with specificity for estradiol Analyst 137 2012 2470 2479
40. M. Schlapschy, U. Binder, C. Börger, I. Theobald, K. Wachinger, S. Kisling, D. Haller, and A. Skerra PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins Protein Eng. Des. Sel. 26 2013 489 501
41. S. Schlehuber, and A. Skerra Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold Biol. Chem. 382 2001 1335 1342